

SCIENTIFIC REPORTS

OPEN

The role of membrane excitability in pancreatic β -cell glucotoxicity

Zeenat A. Shyr¹, Zhiyu Wang^{1,4}, Nathaniel W. York², Colin G. Nichols^{1,2,3} & Maria S. Remedi^{1,2,3}

Received: 28 March 2018
Accepted: 11 January 2019
Published online: 06 May 2019

Persistent hyperglycemia is causally associated with pancreatic β -cell dysfunction and loss of pancreatic insulin. Glucose normally enhances β -cell excitability through inhibition of K_{ATP} channels, opening of voltage-dependent calcium channels, increased $[Ca^{2+}]_i$, which triggers insulin secretion. Glucose-dependent excitability is lost in islets from K_{ATP} -knockout (K_{ATP} -KO) mice, in which β -cells are permanently hyperexcited, $[Ca^{2+}]_i$ is chronically elevated and insulin is constantly secreted. Mouse models of human neonatal diabetes in which K_{ATP} gain-of-function mutations are expressed in β -cells (K_{ATP} -GOF) also lose the link between glucose metabolism and excitation-induced insulin secretion, but in this case K_{ATP} -GOF β -cells are chronically underexcited, with permanently low $[Ca^{2+}]_i$ and lack of glucose-dependent insulin secretion. We used K_{ATP} -GOF and K_{ATP} -KO islets to examine the role of altered-excitability in glucotoxicity. Wild-type islets showed rapid loss of insulin content when chronically incubated in high-glucose, an effect that was reversed by subsequently switching to low glucose media. In contrast, hyperexcitable K_{ATP} -KO islets lost insulin content in both low- and high-glucose, while underexcitable K_{ATP} -GOF islets maintained insulin content in both conditions. Loss of insulin content in chronic excitability was replicated by pharmacological inhibition of K_{ATP} by glibenclamide. The effects of hyperexcitable and underexcitable islets on glucotoxicity observed in *in vivo* animal models are directly opposite to the effects observed *in vitro*: we clearly demonstrate here that *in vitro*, hyperexcitability is detrimental to islets whereas underexcitability is protective.

In the pancreatic β -cell, ATP-sensitive K^+ (K_{ATP}) channels play a critical role in coupling glucose metabolism to insulin secretion via control of membrane excitability, thereby maintaining blood glucose within a narrow physiologic range¹. Increase in glucose metabolism leads to elevated intracellular ATP/ADP ratio and closure of K_{ATP} channels, with consequent membrane depolarization, leading to opening of voltage-dependent calcium channels and increased $[Ca^{2+}]_i$, which in turn triggers insulin secretion. Conversely, decrease in the metabolic signal opens K_{ATP} channels and suppresses the electrical trigger for insulin secretion¹. Normally, the β -cell responds to chronic high glucose with a compensatory increase in β -cell mass to match the insulin secretory requirement. However, in genetically or otherwise predisposed individuals, β -cells are unable to sustain appropriate insulin secretory response and diabetes develops². Persistent hyperglycemia may also lead to β -cell dysfunction and loss of insulin content³. Underlying mechanisms of this so-called glucotoxicity remain unclear, but the unique capacity of β -cells to increase oxidative phosphorylation in response to glucose availability makes them prone to increased reactive oxygen species production, which may underlie increased levels of oxidative stress markers and augmented apoptotic cell-death found in islets from type-2 diabetic organ donors⁴⁻⁷.

The importance of electrical activity in β -cell function is highlighted by the fact that K_{ATP} gain-of-function (GOF) mutations cause human Neonatal Diabetes Mellitus (NDM)⁸, K_{ATP} GOF polymorphisms are highly associated with type-2 diabetes⁹, and K_{ATP} loss-of-function (LOF) mutations underlie congenital hyperinsulinism (CH) (reviewed in^{1,10,11}). Mouse models of NDM and CH due to genetically altered β -cell membrane excitability have been generated¹²⁻¹⁹. As expected, K_{ATP} -GOF mice, with underexcitable β -cells and permanently low $[Ca^{2+}]_i$, show low circulating insulin levels and develop diabetes^{12,20}. Importantly, as diabetes progresses, K_{ATP} -GOF mice demonstrate a marked loss of insulin content, a typical secondary consequence of glucotoxicity¹². However, the

¹Department of Medicine, Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, Missouri, 63110, USA. ²Department of Cell Biology and Physiology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, Missouri, 63110, USA. ³Center for the Investigation of Membrane Excitability Diseases, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, Missouri, 63110, USA. ⁴Present address: Endocrine Consultants Northwest, Franciscan Medical Group, 1628 South Mildred St. Suite 104, Tacoma, WA, 98465, USA. Correspondence and requests for materials should be addressed to M.S.R. (email: mremedi@wustl.edu)




Figure 1. Schematic representation of the proposed key factors involved in pancreatic β -cell damage. In type-2 diabetes, hyperglycemia-induced hypermetabolism is constitutively coupled to membrane hyperexcitability, high $[Ca^{2+}]_i$ and insulin hypersecretion but in K_{ATP} -LOF (congenital Hyperinsulinism) or K_{ATP} -KO mice hypermetabolism is uncoupled from hyperexcitability and high $[Ca^{2+}]_i$, which are persistently high in these mice. Conversely, in K_{ATP} -GOF induced neonatal diabetes, hyperglycemia-induced hypermetabolism is uncoupled from hyperexcitability and high $[Ca^{2+}]_i$ since they are constitutively low in these mice. Grey boxes represent the initial changes, and some of them have been attributed to cause beta-cell damage, as pointed by red arrows.

paradigmatic understanding that this glucotoxic loss of insulin content is the result of β -cell death is challenged by the demonstration of β -cell dedifferentiation, with no significant increase in apoptosis in pancreases from either diabetic mice or human type-2 diabetic organ donors^{21–23}. Critically, we have demonstrated that this loss of β -cell mass in K_{ATP} -GOF mice is caused by loss of mature β -cell identity and dedifferentiation to neurogenin3+/insulin negative cells, rather than apoptotic cell death²².

Chronic hyperglycemia will lead to hyperstimulated metabolism, which will be constitutively coupled to hyperexcitability and chronically elevated $[Ca^{2+}]_i$, factors that have all been suggested to play a role in diabetic loss of β -cell function (Fig. 1). Moreover, decreased insulin secretion and mRNA and increased β -cell death have been demonstrated in multiple *in vitro* studies^{2,3,24,25}. However, K_{ATP} -LOF and K_{ATP} -knockout (KO) mice, with chronically hyperexcitable β -cells and persistently elevated $[Ca^{2+}]_i$, do not show any obvious changes in insulin content or β -cell mass^{15,16,18,26,27}, and K_{ATP} -KO islets have been reported to be less susceptible to the toxic effects of high glucose, oxidative stress and death²⁸. Conversely, as discussed, there is dramatic secondary loss of insulin content in K_{ATP} -GOF mice that is not predicted as a direct consequence of their permanent *underexcitability* and low $[Ca^{2+}]_i$.

In this study, we sought to determine the role of excitability in glucotoxic β -cell failure, and to ask whether this glucotoxicity is induced by hypermetabolism *per se*, or by the normally obligatorily coupled hyperexcitability and high $[Ca^{2+}]_i$. To do this, we have examined insulin content and secretion under glucotoxic conditions in islets isolated from mice in which the link between β -cell metabolism and excitability is lost. We have achieved this both genetically, using (i) islets from K_{ATP} -GOF mice with *underexcitable* β -cells and permanently low $[Ca^{2+}]_i$, and (ii) from K_{ATP} -KO mice with *hyperexcitable* β -cells with chronically elevated $[Ca^{2+}]_i$ (Fig. 1), and pharmacologically by treatment of wild type islets with chronic K_{ATP} channel activator (diazoxide) or inhibitor (glibenclamide). We demonstrate that *underexcitability* is protective against glucotoxic conditions *in vitro*, while hyperexcitability induces loss of insulin content even under low-glucose conditions. These results do not correlate with those obtained *in vivo*, where animal models of altered β -cell excitability show the opposite effects, highlighting the importance of whole body physiology.

Results

Morphological changes induced by high glucose in islets with normal or altered membrane excitability. To directly test the influence of membrane excitability on glucotoxicity in β -cells, islets with normal (wild-type, K_{ATP} -WT), or with genetically increased- (Kir6.2 knockout: K_{ATP} -KO) or decreased-membrane excitability (Pdx-Cre/Kir6.2[K185Q, Δ N30] gain-of-function: K_{ATP} -GOF) were isolated from adult mice and chronically incubated in low (3 mM) or high (30 mM, mimicking the glucose concentration that islets are exposed in K_{ATP} -GOF mice) glucose for up to two weeks. Independent of the glucose concentration, or the genetically altered membrane excitability, the number of intact islets remaining in the dish did not change significantly over the period of time tested (at time 0: 30 ± 0 islets/dish on each genotype, after 10 day incubation: K_{ATP} -WT: 27.4 ± 0.91 islets/dish, K_{ATP} -GOF: 25.8 ± 1.2 islets/dish and K_{ATP} -KO: 24.6 ± 1.6 islets/dish). However, K_{ATP} -WT islets exposed to chronic high glucose became noticeably more translucent than islets incubated in low glucose (Fig. 2a,b) and were larger in diameter (Fig. 2c). K_{ATP} -KO islets (with increased membrane excitability) incubated in low glucose were more translucent at low or high glucose compared to control and K_{ATP} -GOF islets under the same conditions (Fig. 2a,b). Conversely, islets from K_{ATP} -GOF mice (with decreased excitability) maintained their morphology and diameter (Fig. 2) suggesting that membrane *underexcitability* is protective.

Electrophysiology of islets chronically incubated in low and high glucose. We performed current clamp recordings of membrane potential and voltage clamp recording of membrane conductance and capacitance using β -cells isolated from K_{ATP} -WT islets chronically incubated in low and high glucose. Figure 3 shows representative traces (a) and averages (b) of the membrane potential of β -cells (i) chronically incubated in low (3 mM) glucose following break-in in 1 mM glucose (blue), or (ii) chronically incubated in high (30 mM) glucose




Figure 2. Islet Morphology. (a) Representative picture of pancreatic islets from K_{ATP} -WT or genetically altered mice 9 days after incubation in low or high glucose. (b) Quantification of mean gray values (A.U) for islet translucency on K_{ATP} -WT (black), K_{ATP} -KO (red) or K_{ATP} -GOF (green) islets chronically incubated in low- or high-glucose. $n = 3$ experiments from 9 independent mice, experiments were done in triplicates. Significant differences * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ and **** $p < 0.0001$ under the same condition; non-significant differences are not indicated in the figure. (c) Quantification of islet area (mm^2) on K_{ATP} -WT (black), K_{ATP} -KO (red) or K_{ATP} -GOF (green) islets chronically incubated in low- or high-glucose. $n = 3$ experiments from 9 independent mice, experiments were done in triplicates.

following break-in in 10 mM glucose (orange). As predicted for normal K_{ATP} behavior, the first are hyperpolarized (mean $V_m = -64 \pm 2$ mV) due to active K_{ATP} channels (blue), whereas the second are depolarized (mean $V_m = -49 \pm 4$ mV), but then hyperpolarize as K_{ATP} spontaneously activates following break-in (orange). Figure 3c shows voltage-clamp recording of membrane currents in response to voltage ramps (from -120 to -40 mV) from a cell chronically incubated in low (3 mM) glucose after break-in (in 1 mM glucose, blue), then after with spontaneous activation to maximum K_{ATP} (orange), then following subsequent K_{ATP} rundown (grey). The average maximum K_{ATP} current density in cells chronically incubated in 3 or 30 mM glucose is shown in Fig. 3d. K_{ATP} currents are present in both after the 10 day incubation period, although smaller in cells chronically incubated in high glucose. Figure 3e shows that cell capacitance, directly related to cell surface area, is approximately




Figure 3. Beta-cell electrophysiology. **(a)** Representative traces of membrane potential during current clamp recordings from β -cells of K_{ATP} -WT islets chronically incubated in 3 mM glucose (blue) or 30 mM glucose (orange) in bath solution containing 1 mM or 10 mM glucose, respectively. **(b)** Average membrane potential upon break into β -cells from islets chronically incubated in 3 mM or 30 mM glucose. **(c)** Representative traces of current density in β -cell from islets chronically incubated in 3 mM glucose showing break-in current (blue), current at maximal K_{ATP} activation (orange) and current after K_{ATP} rundown (grey). **(d)** Average current density at -120 and -40 mV during maximal K_{ATP} activation is shown from islets chronically incubated at 3 mM ($n = 13$, blue) and 30 mM ($n = 23$, orange) glucose. **(e)** Capacitance of β -cells from islets chronically incubated in 3 mM (blue) and 30 mM (orange) glucose.

doubled in cells from islets chronically incubated in high glucose, correlating with the observed increased in islet area (Fig. 2c).

Insulin content in islets from genetically altered mice chronically exposed to high glucose.

K_{ATP} -WT islets incubated in high glucose demonstrated a marked and rapid reduction of initial insulin content (to $\sim 40\%$), over the first 3 days, which was subsequently maintained with no further decline over longer incubation times (Fig. 4a, black circles and squares, solid lines). This early reduction in insulin content was dramatically reversed in islets that were switched back to low glucose after 3 days incubation in high glucose, indicating a reversible effect with no permanent damage (Fig. 4a, black dashed line). Conversely, K_{ATP} -WT islets incubated in low glucose showed only a minimal reduction of insulin content over a period of 10 days. Strikingly, islets from K_{ATP} -KO mice (with increased membrane excitability and chronically elevated $[Ca^{2+}]_i^{16}$) also demonstrated a rapid (3 days) reduction of insulin content to a similar plateau as K_{ATP} -WT islets, independent of whether incubated in low or high glucose (Fig. 4a, red circles and squares, solid lines). The reduction in insulin content observed in K_{ATP} -KO islets at low glucose was slightly greater when incubated in high glucose, and again this was reversed to the level maintained in low glucose when the media was switched from high to low glucose (Fig. 4a, red dashed line).

As we previously described, K_{ATP} -GOF mice (with reduced β -cell excitability¹² and chronically low $[Ca^{2+}]_i^{20}$), demonstrate severe diabetes within 2 weeks of tamoxifen induction of transgene expression. *In vivo*, this




Figure 4. Glucotoxic changes in islet insulin content *in vitro* depend on membrane excitability. **(a)** Insulin content over time in islets from K_{ATP}-WT (black), K_{ATP}-KO (red) or K_{ATP}-GOF (green) mice chronically incubated in 3 mM (circles, solid line) or 30 mM (squares, solid line) glucose, or when media has been switch from high to low glucose (dashed lines). n = 3 experiments from 6 independent mice, experiments were done in triplicates. Significant differences *p < 0.05 respect to control under the same condition; non-significant differences are not indicated in the figure. **(b)** Total insulin content per islet at day 0 of incubation from K_{ATP}-WT (black), K_{ATP}-KO (red) or K_{ATP}-GOF (green) mice. **(c)** Insulin secreted into the media from K_{ATP}-WT (black), K_{ATP}-KO (red) or K_{ATP}-GOF (green) islets chronically incubated in 3 mM or 30 mM glucose at day 3.

is followed by reduction in β -cell mass and insulin content due to dedifferentiation from mature β -cells to progenitor-like cells, secondary consequences of chronic systemic diabetes^{12,22}, which include correlate loss of insulin and elevation of glucose. To specifically isolate the influence of electrical activity in glucotoxic conditions, islets from K_{ATP}-GOF mice were harvested 10 days after tamoxifen-induction (i.e. prior to development of secondary consequences)¹² and then chronically incubated in low or high glucose *in vitro*. In contrast to WT and K_{ATP}-KO islets, insulin content of K_{ATP}-GOF islets was completely preserved at low glucose, and only slightly reduced at high glucose (Fig. 4a, green circles and squares, solid lines), and again was completely reversed by switching the media from high to low glucose (Fig. 4a, green dashed line). These results indicate that membrane

underexcitability protects from loss of insulin content in these glucotoxic conditions. K_{ATP} -WT, K_{ATP} -GOF and K_{ATP} -KO islets all had similar total islet insulin content on day 0 (Fig. 4b). As predicted, islets from K_{ATP} -KO mice demonstrate insulin hypersecretion when chronically incubated in low (3 mM) glucose, while K_{ATP} -WT and K_{ATP} -GOF do not secrete insulin in this condition (Fig. 4c, left). Moreover, while islets from K_{ATP} -WT mice secrete insulin when incubated in 30 mM glucose media, K_{ATP} -GOF show blunted secretion due to the mutation as expected (Fig. 4c, right).

High glucose effect on islets with pharmacologically altered membrane excitability. An alternative approach to manipulate membrane excitability is pharmacologically. WT islets were chronically incubated with the sulfonylurea glibenclamide (K_{ATP} channel inhibitor) to increase membrane excitability, or with diazoxide (K_{ATP} channel activator) to decrease membrane excitability, in parallel to the genetic approach above. As above, WT islets chronically incubated in high glucose demonstrated a marked decrease in insulin content compared to islets incubated in low glucose (Fig. 5a). Glibenclamide treatment caused a significant loss of insulin content in WT islets incubated in either low or high glucose (Fig. 5a). Conversely, diazoxide-treatment of WT islets resulted in preservation of insulin content in both low and high glucose conditions (Fig. 5a). These results mirror those obtained from K_{ATP} -KO and K_{ATP} -GOF islets, respectively (Fig. 4). To examine the consequences of insulin depletion *per se* in these experiments, exogenous insulin was added to WT islets incubated in low and high glucose. We demonstrate here that insulin prevented the high glucose-induced loss of insulin content (Fig. 5a).

Effects of chronic pharmacologically increased or decreased excitability on glucose-dependent insulin secretion. We examined the insulin secretory response to glucose challenge in WT islets incubated for 10 days in low or high glucose, in the absence or presence of K_{ATP} channel inhibitors or activators. WT islets chronically incubated in low glucose secreted insulin normally in response to acute high glucose stimulation (Fig. 5b). However, WT islets that had been chronically incubated in high glucose showed an unexpectedly high basal insulin secretion in response to acute low glucose, but blunted response to acute high glucose (Fig. 5c). Importantly, WT islets chronically incubated in low or high glucose in the presence of glibenclamide also showed increased insulin secretion when acutely exposed to low glucose (Fig. 5b), and a marked decrease in insulin secretion when exposed to high glucose for one hour (Fig. 5c). Conversely, islets chronically incubated with diazoxide (K_{ATP} activator, which results in electrical ‘rest’) demonstrated both increased basal and glucose-stimulated insulin secretion, compared to islets exposed to glucose alone (Fig. 5b,c). When insulin secretion was calculated as a fraction of insulin content, it is clear that chronic glibenclamide acutely stimulates increased basal secretion, whereas diazoxide inhibits glucose-dependent secretion, in both cases (Fig. 5b,c, inserts).

Proinsulin is increased in islets exposed to chronic high glucose. Because of the dramatic decrease in insulin content, we tested whether proinsulin biosynthesis was altered in genetically altered or pharmacologically treated islets. All islets exposed to chronic high glucose demonstrated a significant increase in proinsulin content, independent of the genotype (Fig. 6a) or pharmacologic treatment (Fig. 6b). At time 0, K_{ATP} -KO islets showed lower proinsulin content than WT (Fig. 6a, red circles and squares), whereas K_{ATP} -GOF islets demonstrated a markedly higher proinsulin level (Fig. 6a, green circles and squares). Conversely, all islets exposed to chronic low glucose demonstrated a significant decrease in proinsulin content over time, independent of the genotype (Fig. 6a) or pharmacologic treatment (Fig. 6b). These results demonstrate quite clearly that there is a positive effect of high glucose on proinsulin content, irrespective of membrane excitability.

Discussion

Chronic effects of hyperglycemia on islet function. Progressive deterioration in β -cell function, increased levels of oxidative stress markers, loss of insulin content and decreased β -cell mass *in vivo* have long been recognized in the pathogenesis of type-2 diabetes^{4–6,24}, regardless of therapy^{7,29}. Chronic hyperglycemia and elevated free fatty-acids negatively impact β -cell function and insulin secretion, but mechanisms underlying secondary loss of insulin remain unclear. In otherwise normal islets, chronic hyperglycemia will cause a persistent increase in membrane excitability and permanently elevated $[Ca^{2+}]_i$, potential key factors in deterioration of β -cell function ultimately leading to β -cell death^{30,31}. However, this paradigm of β -cell death in diabetes has now been challenged by the demonstration of loss of pancreatic β -cell identity and cell dedifferentiation in both mouse and human diabetes^{21–23,32}. The largely unknown and potentially detrimental effects of abnormally high or low $[Ca^{2+}]_i$ prompts us to ask the question: What role does membrane hyper- or hypo-excitability *per se*, and the consequently high or low $[Ca^{2+}]_i$, play in the deleterious effects of high glucose on islet function. By incubating islets from mice with genetically enhanced or reduced membrane excitability (i.e. K_{ATP} -KO and K_{ATP} -GOF mice respectively) in chronic high glucose *in vitro*, we can separate the role of excitability from otherwise linked *in vivo* factors in any glucotoxic response.

The role of membrane excitability in glucotoxicity. The unique capacity of β -cells to increase oxidative phosphorylation in response to glucose availability makes them prone to increased reactive oxygen species production, which may lead to mitochondrial dysfunction and ultimately cell death. In WT islets, the marked reduction of insulin content and glucose-stimulated insulin secretion (GSIS) when chronically incubated in high glucose is consistent with earlier studies demonstrating that rodent β -cells adapt to chronic high glucose by reducing maximal GSIS, but without alterations in pancreatic islet mass³³. The maintenance of insulin content in K_{ATP} -GOF islets exposed to high glucose indicates that reduced membrane excitability protects them against such a loss of insulin content *in vitro*. In addition, this finding argues against any primary role of underexcitability and low $[Ca^{2+}]_i$ ²⁰ in the loss of β -cell mass and especially insulin content that are observed in K_{ATP} -GOF islets *in vivo*^{12,22,34}.




Figure 5. Chronic pharmacologic manipulation of membrane excitability alters insulin content and secretion. (a) Insulin content in WT islets incubated for 10 days in 3 mM and 30 mM glucose, or plus the addition of the K_{ATP} channel inhibitor glibanclamide (1 μ M) or the activator diazoxide (250 mM), or insulin (20 nM). Significant differences * $p < 0.05$ with respect to control under the same condition, non-significant are not indicated in the figure. Insulin secretion response to acute low (light grey bars) or high (dark grey bars) glucose stimulated insulin secretion on WT islets chronically exposed to low glucose (b) or high glucose (c) plus glibanclamide or diazoxide. Significant differences * $p < 0.05$ with respect to chronic glucose alone under the same stimulatory condition, non-significant differences are not indicated in the figures. Inserts represent insulin secretion as a fraction of content.

Conversely, reduced insulin content in K_{ATP} -KO mouse islets after chronic incubation in either low or high glucose suggests that chronic membrane hyperexcitability is a major determinant of insulin loss *in vitro*. Although there is no significant reduction in β -cell mass in normoglycemic K_{ATP} -KO mice^{15,16,35}, these results suggest that




Figure 6. Changes in proinsulin content *in vitro* in islets genetically altered or pharmacologically treated with K_{ATP} channel inhibitors and activators. **(a)** Proinsulin content at 0, 3 and 9 days on K_{ATP}-WT (black), K_{ATP}-KO (red) or K_{ATP}-GOF (green) islets chronically incubated in low or high glucose. **(b)** Proinsulin content at 0, 3 and 9 days on WT islets chronically incubated in low or high glucose with or without the addition of glibenclamide (pink) or diazoxide (blue).

elevated [Ca²⁺]_i will be detrimental in the setting of hyperglycemia, consistent with studies indicating that high [Ca²⁺]_i is a key factor in reduction of β-cell functionality in diabetes^{15,16,30,31,35}.

Is increased membrane excitability, independent of altered metabolism, responsible for reduced insulin content?

Consistent with the idea that chronic β-cell hyperexcitability leads to a persistently elevated [Ca²⁺]_i, and insulin hypersecretion with depletion of insulin stores^{24,36}, our *in vitro* data show that increasing membrane excitability, either genetically (K_{ATP}-KO islets) or pharmacologically (glibenclamide-treated islets), does indeed lead to marked reduction in insulin content over ~3 days. Conversely, islets with genetically (K_{ATP}-GOF islets) or pharmacologically (diazoxide-treated) reduced membrane excitability maintain insulin content over the full 10 days, even when they are chronically incubated in high glucose. Persistent inhibition of WT K_{ATP} channels with glibenclamide induces similar reduction of insulin content to that observed in K_{ATP}-KO islets. These results correlate with studies demonstrating reduction of GSIS in rodent and human islets chronically incubated with sulfonylurea drugs, although these effects have only been observed *in vitro*, and not with consistency^{36–38}. In addition, these results correlate with our previous observations that, in islets chronically exposed to glibenclamide, there is a mild increase in DNA synthesis; an effect that was completely abrogated by the presence of nifedipine (a calcium channel inhibitor), arguing that it is indeed driven by elevated [Ca²⁺]_i³⁹. Moreover, our results are also consistent with those showing that islets chronically incubated in, or re-exposed to, sulfonylureas exhibited insulin secretion that occurs at lower [glucose] and accompanied by reduction in the maximal insulin response^{40,41}.

Preserved insulin content and maintained GSIS (Fig. 4) in WT islets exposed to high glucose in the presence of diazoxide mimicked the effect observed in underexcited K_{ATP}-GOF islets, supporting the hypothesis that 'rest' from hyperexcitability and therefore from chronically elevated [Ca²⁺]_i is protective against depletion of insulin content, and potentially against Ca²⁺-dependent apoptosis^{24,36}. WT islets incubated in the presence of high glucose plus diazoxide have been reported to be more glucose sensitive, and to show a left-shift in glucose-stimulated insulin secretion, as well as a marked increase in DNA synthesis without changes in plasma K_{ATP} channels^{39,42,43}. However, changes in β-cell oscillatory [Ca²⁺]_i and K_{ATP} conductance and a shift in glucose sensitivity have also been reported in islets incubated overnight with high glucose plus diazoxide⁴⁴ which is consistent with altered K_{ATP} trafficking to the plasma membrane. Our results also correlate with decreased insulin content and secretion in human islets incubated in high glucose for 4 days, effects that were partially reversed by addition of diazoxide in the incubation media⁴⁵.

The concept of deficient insulin stores as a contributing factor to β-cell dysfunction in type-2 diabetes arose many years ago, based on the observation that type-2 diabetic patients show restoration of insulin response to oral sulfonylurea stimulation after a period of treatment with diazoxide or insulin, in order to induce β-cell 'rest'^{46–49}. Diazoxide treatment has also been shown to improve subsequent β-cell secretory function in 90% pancreatectomized diabetic rats and in streptozotocin-diabetic rats⁵⁰, and to reverse the marked loss of glucose-induced rise in [Ca²⁺]_i in human islets exposed to chronic high glucose⁵¹. Taken together, these *in vitro* and *in vivo* studies implicate electrical excitability-dependent loss of β-cell insulin content in high glucose conditions, which can be restored after exposure to low glucose and consequent suppression of excitation. Normally, islets do not accumulate large amounts of proinsulin since it is processed into mature insulin, which is then secreted. We began culturing islets from K_{ATP}-GOF mice at day 10 post tamoxifen at which point these mice are already hyperglycemic (>30 mM blood glucose levels) due to lack of insulin secretion. This will drive enhanced glucose metabolism, and since proinsulin biosynthesis is induced in response to glucose metabolism, elevated proinsulin in these islets may be expected⁵². In the K_{ATP}-KO model, since insulin is persistently secreted (reflected in accumulation of insulin in the media in low glucose condition), proinsulin accumulation is minimal. As expected, when any islets (controls, K_{ATP}-GOF or K_{ATP}-KO) are exposed to chronically high glucose, they showed increased proinsulin synthesis in response to elevated glucose in the media.

While precise mechanisms underlying the decrease in insulin content are not clear, our finding of increased proinsulin in all islets incubated in high glucose is consistent with inefficient conversion of proinsulin to insulin, potentially due to chronic glucose-induced oxidative and endoplasmic reticulum stress. It has been shown that, while glibenclamide increases and diazoxide decreases insulin secretion, there is no effect of these drugs on proinsulin biosynthesis (reviewed in⁵³). These results are consistent with our observations that islets chronically incubated in high glucose, whether in the presence of either glibenclamide or diazoxide (which induce opposite effects on excitability and $[Ca]_i$), leads to increased proinsulin, thus highlighting the effect of high glucose itself on proinsulin accumulation, rather than membrane excitability *per-se*. Our results also correlate with those demonstrating decreased proinsulin/insulin ratio in human islets treated with diazoxide at 11 mM glucose, which, by reducing excitability, preserves insulin content⁴⁵. In obese mouse models of type-2 diabetes, islet proinsulin synthesis is typically increased and is accompanied by decreased mature insulin granules, due to dysfunctional insulin processing, effects that are reversed following incubation in low glucose media⁵⁴. Consistent with the findings in rodent islets, human islets exposed to high glucose show accumulation and preferential secretion of proinsulin, secondary to depletion of mature insulin granules⁵⁵.

Exogenous insulin prevention of high glucose-induced loss of insulin content. We have previously demonstrated that inclusion of insulin in the incubation media can protect islets from loss of endogenous insulin content³⁹. Preservation of insulin content in WT islets that were co-incubated with high glucose and insulin is consistent with studies that demonstrate better preservation of β -cell function in newly diagnosed type-2 diabetic patients subjected to intensive insulin therapy than in those treated with sulfonylureas^{7,46}. It has also previously been shown that insulin can acutely induce membrane hyperpolarization by activation of K_{ATP} channels⁵⁶, although such a mechanism seems unlikely to contribute to the chronic preservation of insulin in the current experiments. At higher concentrations, DNA synthesis and islet proliferation can be induced by exogenous insulin³⁹, but this is not likely at the concentration used in the present study.

***In vitro* versus *in vivo* models of glucotoxicity.** We demonstrate here that chronic membrane hyperexcitability induced by high glucose conditions underlies loss of insulin content, and that membrane underexcitability protects islets from high glucose-induced loss of insulin content *in vitro*. It is important to note that pancreatic β -cells from mice with altered membrane excitability show the opposite long-term outcomes *in vivo*. We and others have previously demonstrated a marked reduction of insulin content, β -cell mass and insulin mRNA in islets from K_{ATP} -GOF diabetic mice with reduced membrane excitability^{12–14,22,34}. This is the result of chronic systemic diabetes and correlates with findings demonstrated in other forms of diabetes^{21,33,57}. The primary mechanism for loss of insulin was shown to be pancreatic β -cell dedifferentiation to progenitor-like cells in the severely diabetic state, with re-differentiation to mature β -cells following lowering of blood glucose by intensive insulin therapy^{22,33}. Conversely, islets with chronically increased membrane excitability and increased $[Ca^{2+}]_i$ (from K_{ATP} -KO^{15,16,18} and K_{ATP} -LOF mice^{20,26}) show preserved insulin content *in vivo*. Moreover, chronic pharmacologic treatment with glibenclamide leading to increase in membrane excitability did not demonstrate any significant reduction in pancreatic islet insulin content *in vivo*³⁵.

These differences observed *in vivo* versus *in vitro* may arise from the shorter duration of exposure to high glucose typically examined *in vitro*, including in this study, which might not be sufficient for the long-term consequences detected *in vivo* to occur. In addition, the *in vitro* absence of other nutrients such as amino acids and incretin hormones, which are known modulators of β -cell sensitivity to glucose, may contribute to *in vivo* consequences. We previously demonstrated that the *in vivo* environment is important for the islet response in K_{ATP} -GOF mice. Severely diabetic K_{ATP} -GOF mice show increased glucose metabolism at non-stimulatory glucose concentrations²⁰, whereas K_{ATP} -GOF mice treated acutely with glibenclamide at disease onset can enter a sustained remission and maintain near normoglycemia³⁴, effects that are characteristic of other animal models of β -cell overstimulation and diabetes^{34,35,58}. Finally, it is also important to note that the types of stresses that β -cells are exposed to *in vitro* (e.g. islet isolation from vascularization, loss of endothelial cells, and changes in intracellular matrix) are absent *in vivo* and could influence the response to high glucose exposure. Thus, other *in vivo* factors could also play a role in the marked loss of drug responsiveness, β -cell function deterioration, reduction of insulin content and loss of β -cell mass in diabetes¹¹.

β -cell rest from hypermetabolism, hyperexcitability or hypersecretion? What does 'rest' mean in potential recovery from β -cell dysfunction? Finally, there has been much interest in the idea that exogenous insulin (and insulin plus diazoxide) treatment leads to β -cell 'rest', and that this permits restoration of β -cell function. It is unclear exactly what 'rest' means in this context: Does it mean rest from hyperstimulated metabolism, hyperexcitation, elevated $[Ca^{2+}]_i$, or from insulin secretion? Some studies clearly lean towards rest meaning rest from secretion. The present study provides one clear answer: our results show that rest from hyperexcitability (and its downstream consequences) is the key determinant of maintenance of insulin content *in vitro*. K_{ATP} -GOF islets (or WT islets treated with diazoxide), which are permanently in the 'resting' state in terms of excitability, $[Ca^{2+}]_i$, and insulin secretion maintain insulin content even in the chronic metabolically stimulated state of hyperglycemia. Conversely, K_{ATP} -KO islets (or WT islets treated with glibenclamide), which are chronically excited, lose insulin content rapidly in both high and low glucose conditions.

Methods

Mouse models of altered membrane electrical activity. All experiments were performed in compliance with the institutional guidelines of, and approved by, the Washington University Animal Studies Committee. K_{ATP} knockout¹⁶ and tamoxifen-inducible $Pdx1^{PB}Cre^{ERTM}$ β -cell specific K_{ATP} -GOF (Kir6.2 [K185Q, Δ N30])¹² mutant mice were previously generated. Control littermates were used in all experiments.

Pancreatic islet isolation. Mice were anesthetized with Isoflurane (0.2 ml) and killed by cervical dislocation, and the bile duct was cannulated and perfused with Hank's solution (Sigma) containing collagenase (Collagenase Type XI, Sigma). The pancreas was removed and digested at 37°C, hand shaken and washed in cold Hank's solution. Islets were isolated by hand under a dissecting microscope and maintained overnight in CMRL-1066 (5.6 mM glucose) culture medium (GIBCO) supplemented with fetal calf serum (10%), penicillin (100 U/ml), and streptomycin (100 µg/ml)¹².

Islet morphology measurements. Following overnight incubation in CMRL media containing 5.6 mM glucose, 30 islets per group were chronically incubated for 10 days in CMRL-1066 containing low (3 mM) or high (30 mM) glucose (experiment done in triplicates). On day 9, islets images were obtained using the Leica DMI 4000B inverted microscope (Leica microsystems, IL) under bright field. Islet mean grey value and islet area were analyzed by Fiji (ImageJ).

Electrophysiological experiments. Whole cell recordings were made using an Axopatch 200B amplifier and Digidata 1200 (Molecular Devices), as reported previously⁵⁹. Voltage clamp recordings were performed using a ramp protocol from -120 mV to $+40$ mV with cells held at -70 mV during the inter-pulse interval. The bath solution was Tyrode's solution contained 137 mM NaCl, 5.4 mM KCl, 1 mM MgCl₂, 2 mM CaCl₂, 0.33 mM NaH₂PO₄, 5 mM HEPES and 1 mM Glucose with pH adjusted to 7.4 mM with NaOH. The pipette solution contained 120 mM KCl, 10 mM HEPES and 1 mM K-EGTA, with pH adjusted to 7.4. For current clamp recordings current was held at 0 pA. The bath solution used for current clamp recordings contained 10 mM glucose for cells from islets chronically incubated in 30 mM glucose and was unaltered for cells from islets chronically incubated at 3 mM glucose. Glass electrodes were pulled from Kimble-Chase 2502 plain capillary tubes using a P-87 puller (Sutter instruments). For voltage clamp recordings electrodes with 1–3 MΩ tips were used and for current clamp recordings 5–7 MΩ tips were used.

Islet manipulation and measurement of insulin secretion and content. 30 islets per group were incubated at low (3 mM) or high (30 mM) glucose and were collected at day 3, 6 and 9 for measurement of insulin content. Insulin secreted in the media under 3 and 30 mM glucose conditions was measured on day 3. For reversibility experiments, isolated islets were incubated with high glucose for several days and then the media was changed to low glucose for the time indicated in the figures. Additionally, wild-type islets were chronically incubated for 10 days in low or high glucose in the presence of 1 µM glibenclamide or 250 µM diazoxide (to block or activate K_{ATP} and thereby pharmacologically increase or decrease membrane excitability, respectively), or in the presence of 20 nM insulin. After the chronic treatment period, the islets were counted, and then pre-incubated in groups of 10 per well in 12 well plates in glucose-free CMRL-1066 plus 3 mM glucose, then incubated for 1 hour at 37°C in CMRL-1066 plus low (3 mM) or high (30 mM) glucose for insulin secretion experiments. After the incubation period, the medium was removed and assayed for released insulin. Experiments were repeated in triplicate. For islet insulin content, groups of 10 islets were disrupted using ethanol-HCl extraction and sonicated on ice for estimation of insulin content. Insulin secretion and content were measured using either Rat Insulin radioimmunoassay (RIA, Millipore, St. Charles, MO)²² or Ultrasensitive Mouse Insulin Elisa kit (Crystal Chem, Elk Grove Village, IL)⁶⁰ according to manufacturer's procedure²².

Measurement of proinsulin content in islets. Islets were incubated overnight in CMRL media containing 5.6 mM glucose prior to all experiments. On days 0, 3, and 9, replicates of 10 islets per genotype was collected in microcentrifuge tubes, washed with PBS and re-suspended in acid-ethanol extraction buffer. Proinsulin content was calculated by utilizing the Mouse Proinsulin Elisa (Mercodia, Salem NC).

Statistics. Data are presented as mean ± SEM. Differences among groups were tested using analysis of variance (ANOVA) and post-hoc Duncan's test. When only two groups were compared, unpaired t-tests were used to assess significance. *Indicates significant differences, with $p < 0.05$ respect to control condition. **Indicates significant differences $p < 0.01$, *** $p < 0.001$ and **** $p < 0.0001$.

References

- Remedi, M. S. & Koster, J. C. KATP channelopathies in the pancreas. *Pflugers Arch* **460**, 307–320 (2010).
- Prentki, M. & Nolan, C. J. Islet beta cell failure in type 2 diabetes. *J Clin Invest* **116**, 1802–1812 (2006).
- Poitout, V. & Robertson, R. P. Glucolipotoxicity: fuel excess and beta-cell dysfunction. *Endocr Rev* **29**, 351–366 (2008).
- Cnop, M. *et al.* Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. *Diabetes* **54**(Suppl 2), S97–107 (2005).
- Del Guerra, S. *et al.* Functional and Molecular Defects of Pancreatic Islets in Human Type 2 Diabetes. *Diabetes* **54**, 727–735 (2005).
- Butler, A. E. *et al.* Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes* **52**, 102–110 (2003).
- Wajchenberg, B. L. beta-cell failure in diabetes and preservation by clinical treatment. *Endocr Rev* **28**, 187–218 (2007).
- Gloyn, A. L. *et al.* Activating Mutations in the Gene Encoding the ATP-Sensitive Potassium-Channel Subunit Kir6.2 and Permanent Neonatal Diabetes. *N Engl J Med* **350**, 1838–1849 (2004).
- Villareal, D. T. *et al.* Kir6.2 variant E23K increases ATP-sensitive K⁺ channel activity and is associated with impaired insulin release and enhanced insulin sensitivity in adults with normal glucose tolerance. *Diabetes* **58**, 1869–1878 (2009).
- Stanley, C. A. Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders. *The Journal of clinical endocrinology and metabolism* **101**, 815–826 (2016).
- Remedi, M. S. & Emfinger, C. Pancreatic beta-cell identity in diabetes. *Diabetes Obes Metab* **18**(Suppl 1), 110–116 (2016).
- Remedi, M. S. *et al.* Secondary consequences of beta cell inexcitability: identification and prevention in a murine model of K(ATP)-induced neonatal diabetes mellitus. *Cell Metab* **9**, 140–151 (2009).
- Koster, J. C., Marshall, B. A., Ensor, N., Corbett, J. A. & Nichols, C. G. Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes. *Cell* **100**, 645–654 (2000).
- Girard, C. A. *et al.* Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. *J Clin Invest* **119**, 80–90 (2009).

15. Seghers, V., Nakazaki, M., DeMayo, F., Aguilar-Bryan, L. & Bryan, J. Sur1 knockout mice. A model for K(ATP) channel-independent regulation of insulin secretion. *The Journal of biological chemistry* **275**, 9270–9277 (2000).
16. Miki, T. *et al.* Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice. *Proc Natl Acad Sci USA* **95**, 10402–10406 (1998).
17. Miki, T. *et al.* Abnormalities of pancreatic islets by targeted expression of a dominant-negative KATP channel. *Proc Natl Acad Sci USA* **94**, 11969–11973 (1997).
18. Shiota, C. *et al.* Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. *Journal of Biological Chemistry* **277**, 37176–37183 (2002).
19. Remedi, M. S. *et al.* Hyperinsulinism in mice with heterozygous loss of K(ATP) channels. *Diabetologia* **49**, 2368–2378 (2006).
20. Benninger, R. K. *et al.* Defects in beta cell Ca(2)+ signalling, glucose metabolism and insulin secretion in a murine model of K(ATP) channel-induced neonatal diabetes mellitus. *Diabetologia* **54**, 1087–1097 (2011).
21. Talchai, C., Xuan, S., Lin, H. V., Sussel, L. & Accili, D. Pancreatic beta Cell Dedifferentiation as a Mechanism of Diabetic beta Cell Failure. *Cell* **150**, 1223–1234 (2012).
22. Wang, Z., York, N. W., Nichols, C. G. & Remedi, M. S. Pancreatic beta cell dedifferentiation in diabetes and redifferentiation following insulin therapy. *Cell Metab* **19**, 872–882 (2014).
23. Cinti, F. *et al.* Evidence of beta-cell Dedifferentiation in Human Type 2 Diabetes. *The Journal of clinical endocrinology and metabolism* **101**, 1044–1054 (2015).
24. Robertson, R. P., Harmon, J., Tran, P. O., Tanaka, Y. & Takahashi, H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. *Diabetes* **52**, 581–587 (2003).
25. Nichols, C. G. & Remedi, M. S. The diabetic β -cell: hyperstimulated vs. hyperexcited. *Diabetes, Obesity and Metabolism* **14** (2012).
26. Koster, J. C. *et al.* Hyperinsulinism induced by targeted suppression of beta cell KATP channels. *Proc Natl Acad Sci USA* **99**, 16992–16997 (2002).
27. Rocheleau, J. V. *et al.* Critical Role of Gap Junction Coupled KATP Channel Activity for Regulated Insulin Secretion. *PLoS Biology* **4** (2006).
28. Gier, B. *et al.* Suppression of KATP channel activity protects murine pancreatic beta cells against oxidative stress. *J Clin Invest* **119**, 3246–3256 (2009).
29. UKPDS-group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. *Lancet (London, England)* **352**, 837–853 (1998).
30. Grill, V. & Bjorklund, A. Overstimulation and beta-cell function. *Diabetes* **50**(Suppl 1), S122–124 (2001).
31. Poitout, V. Glucolipotoxicity of the pancreatic beta-cell: myth or reality? *Biochemical Society transactions* **36**, 901–904 (2008).
32. Brereton, M. F. *et al.* Reversible changes in pancreatic islet structure and function produced by elevated blood glucose. *Nat Commun* **5**, 4639 (2014).
33. Jonas, J. C. *et al.* Glucose regulation of islet stress responses and beta-cell failure in type 2 diabetes. *Diabetes Obes Metab* **11**(Suppl 4), 65–81 (2009).
34. Remedi, M. S., Agapova, S. E., Vyas, A. K., Hruz, P. W. & Nichols, C. G. Acute Sulfonylurea Therapy at Disease Onset Can Cause Permanent Remission of KATP-Induced Diabetes. *Diabetes* (2011).
35. Remedi, M. S. & Nichols, C. G. Chronic antidiabetic sulfonylureas *in vivo*: reversible effects on mouse pancreatic beta-cells. *PLoS Med* **5**, e206 (2008).
36. Efanova, I. B. *et al.* Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. *The Journal of biological chemistry* **273**, 33501–33507 (1998).
37. Maedler, K. *et al.* Sulfonylurea induced beta-cell apoptosis in cultured human islets. *The Journal of clinical endocrinology and metabolism* **90**, 501–506 (2005).
38. Del Guerra, S. *et al.* Effects of prolonged *in vitro* exposure to sulphonylureas on the function and survival of human islets. *Journal of Diabetes & its Complications* **19**, 60–64 (2005).
39. Kwon, G. *et al.* Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent islets. *The Journal of biological chemistry* **281**, 3261–3267 (2006).
40. Anello, M., Gilon, P. & Henquin, J. C. Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content. *British journal of pharmacology* **127**, 1883–1891 (1999).
41. Rustenbeck, I., Dickel, C. & Grimmshmanns, T. Desensitization of insulin secretory response to imidazolines, tolbutamide, and quinine. II. Electrophysiological and fluorimetric studies. *Biochem Pharmacol* **62**, 1695–1703 (2001).
42. Ma, Z., Portwood, N., Brodin, D., Grill, V. & Bjorklund, A. Effects of diazoxide on gene expression in rat pancreatic islets are largely linked to elevated glucose and potentially serve to enhance beta-cell sensitivity. *Diabetes* **56**, 1095–1106 (2007).
43. Grill, V., Radtke, M., Qvigstad, E., Kollind, M. & Bjorklund, A. Beneficial effects of K-ATP channel openers in diabetes: an update on mechanisms and clinical experiences. *Diabetes Obes Metab* **11**(Suppl 4), 143–148 (2009).
44. Glynn, E. *et al.* Chronic Glucose Exposure Systematically Shifts the Oscillatory Threshold of Mouse Islets: Experimental Evidence for an Early Intrinsic Mechanism of Compensation for Hyperglycemia. *Endocrinology* **157**, 611–623 (2016).
45. Song, S. H., Rhodes, C. J., Veldhuis, J. D. & Butler, P. C. Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets. *Endocrinology* **144**, 3399–3405 (2003).
46. Alvarsson, M. *et al.* Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. *Diabetes Obes Metab* **10**, 421–429 (2008).
47. Torella, R. *et al.* Restoration of sensitivity to sulfonylurea after strict glycaemic control with insulin in non-obese type 2 diabetic subjects. *Diabetes et Metabolisme* **17**, 443–447 (1991).
48. Weng, J. *et al.* Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. *Lancet (London, England)* **371**, 1753–1760 (2008).
49. Greenwood, R. H., Mahler, R. F. & Hales, C. N. Improvement in insulin secretion in diabetes after diazoxide. *Lancet (London, England)* **1**, 444–447 (1976).
50. Leahy, J. L., Bumbalo, L. M. & Chen, C. Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomized diabetic rats. *Diabetes* **43**, 173–179 (1994).
51. Bjorklund, A., Lansner, A. & Grill, V. E. Glucose-induced [Ca2+]i abnormalities in human pancreatic islets: important role of overstimulation. *Diabetes* **49**, 1840–1848 (2000).
52. Boland, B. B., Rhodes, C. J. & Grimsby, J. S. The dynamic plasticity of insulin production in beta-cells. *Molecular metabolism* **6**, 958–973 (2017).
53. Uchizono, Y., Alarcon, C., Wicksteed, B. L., Marsh, B. J. & Rhodes, C. J. The balance between proinsulin biosynthesis and insulin secretion: where can imbalance lead? *Diabetes Obes Metab* **9**(Suppl 2), 56–66 (2007).
54. Alarcon, C. *et al.* Pancreatic beta-Cell Adaptive Plasticity in Obesity Increases Insulin Production but Adversely Affects Secretory Function. *Diabetes* **65**, 438–450 (2016).
55. Bjorklund, A. & Grill, V. Enhancing effects of long-term elevated glucose and palmitate on stored and secreted proinsulin-to-insulin ratios in human pancreatic islets. *Diabetes* **48**, 1409–1414 (1999).
56. Khan, F. A., Goforth, P. B., Zhang, M. & Satin, L. S. Insulin activates ATP-sensitive K(+) channels in pancreatic beta-cells through a phosphatidylinositol 3-kinase-dependent pathway. *Diabetes* **50**, 2192–2198 (2001).

57. Laybutt, D. R. *et al.* Critical reduction in beta-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes. *The Journal of biological chemistry* **278**, 2997–3005 (2003).
58. Leahy, J. L., Bumbalo, L. M. & Chen, C. Beta-cell hypersensitivity for glucose precedes loss of glucose-induced insulin secretion in 90% pancreatectomized rats. *Diabetologia* **36**, 1238–1244 (1993).
59. Emfinger, C. H. *et al.* Expression and function of ATP-dependent potassium channels in zebrafish islet beta-cells. *R Soc Open Sci* **4**, 160808 (2017).
60. Yan, Z. *et al.* High-fat-diet-induced remission of diabetes in a subset of KATP -GOF insulin-secretory-deficient mice. *Diabetes Obes Metab* (2018).

Acknowledgements

This work was supported by NIH R01 DK098584 to M.S.R., NIH R01 DK109407 to C.G.N. Fellowship support was provided by NIH T32 DK108742 to Z.A.S. and NIH T32 HL125241 to N.W.Y. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Theresa M. Harter and Zihan Yan (Department of Cell Biology and Physiology and Medicine, Washington University School of Medicine, Saint Louis, MO) for assistance with mouse breeding, maintenance and genotyping.

Author Contributions

M.S.R., Z.W., Z.A.S. designed the study and C.G.N. designed the study. M.S.R., Z.W., N.W.Y., C.G.N. and Z.A.S. carried out the experiments and analyzed the data. M.S.R. wrote the paper, Z.A.S. provided comments, and C.G.N. and M.S.R. edited it. M.S.R. is a guarantor of this manuscript.

Additional Information

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019